Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2011 2
2012 2
2014 1
2015 2
2016 2
2017 2
2018 1
2019 2
2020 1
2021 8
2022 5
2023 4
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

31 results

Results by year

Filters applied: . Clear all
Page 1
Irinotecan-Induced Toxicity: A Pharmacogenetic Study Beyond UGT1A1.
de With M, van Doorn L, Kloet E, van Veggel A, Matic M, de Neijs MJ, Oomen-de Hoop E, van Meerten E, van Schaik RHN, Mathijssen RHJ, Bins S. de With M, et al. Among authors: van doorn l. Clin Pharmacokinet. 2023 Nov;62(11):1589-1597. doi: 10.1007/s40262-023-01279-7. Epub 2023 Sep 16. Clin Pharmacokinet. 2023. PMID: 37715926 Free PMC article.
Capecitabine-induced hand-foot syndrome: A pharmacogenetic study beyond DPYD.
de With M, van Doorn L, Maasland DC, Mulder TAM, Oomen-de Hoop E, Mostert B, Homs MYV, El Bouazzaoui S, Mathijssen RHJ, van Schaik RHN, Bins S. de With M, et al. Among authors: van doorn l. Biomed Pharmacother. 2023 Mar;159:114232. doi: 10.1016/j.biopha.2023.114232. Epub 2023 Jan 9. Biomed Pharmacother. 2023. PMID: 36630849 Free article.
Capecitabine and the Risk of Fingerprint Loss.
van Doorn L, Veelenturf S, Binkhorst L, Bins S, Mathijssen R. van Doorn L, et al. JAMA Oncol. 2017 Jan 1;3(1):122-123. doi: 10.1001/jamaoncol.2016.2638. JAMA Oncol. 2017. PMID: 27560202 No abstract available.
Effect of Scalp Cooling on the Pharmacokinetics of Paclitaxel.
van Doorn L, van Rosmalen MM, van der Deure WM, Oomen-de Hoop E, Porrazzo R, Wijngaard SM, Boere IA, Veenstra P, Ibrahim E, de Bruijn P, Friberg LE, Koolen SLW, Mathijssen RHJ, Jager A. van Doorn L, et al. Cancers (Basel). 2021 Aug 3;13(15):3915. doi: 10.3390/cancers13153915. Cancers (Basel). 2021. PMID: 34359815 Free PMC article.
Dietary sodium restriction prevents vascular endothelial growth factor inhibitor-induced hypertension.
van Doorn L, Visser WJ, van Dorst DCH, Mirabito Colafella KM, Koolen SLW, de Mik AVE, Garrelds IM, Bovée DM, de Hoop EO, Bins S, Eskens FALM, Hoorn EJ, Jan Danser AH, Mathijssen RHJ, Versmissen J. van Doorn L, et al. Br J Cancer. 2023 Jan;128(2):354-362. doi: 10.1038/s41416-022-02036-6. Epub 2022 Nov 10. Br J Cancer. 2023. PMID: 36357702 Free PMC article.
Influence of Probenecid on the Pharmacokinetics and Pharmacodynamics of Sorafenib.
Hussaarts KGAM, van Doorn L, Eechoute K, Damman J, Fu Q, van Doorn N, Eisenmann ED, Gibson AA, Oomen-de Hoop E, de Bruijn P, Baker SD, Koolen SLW, van Gelder T, van Leeuwen RWF, Mathijssen RHJ, Sparreboom A, Bins S. Hussaarts KGAM, et al. Among authors: van doorn l. Pharmaceutics. 2020 Aug 20;12(9):788. doi: 10.3390/pharmaceutics12090788. Pharmaceutics. 2020. PMID: 32825359 Free PMC article.
Differential effects of cyclo-oxygenase 1 and 2 inhibition on angiogenesis inhibitor-induced hypertension and kidney damage.
Mirabito Colafella KM, van Dorst DCH, Neuman RI, Doorn LV, Neves KB, Montezano AC, Garrelds IM, van Veghel R, de Vries R, Uijl E, Clahsen-van Groningen MC, Baelde HJ, van den Meiracker AH, Touyz RM, Visser W, Danser AHJ, Versmissen J. Mirabito Colafella KM, et al. Among authors: doorn lv. Clin Sci (Lond). 2022 May 13;136(9):675-694. doi: 10.1042/CS20220182. Clin Sci (Lond). 2022. PMID: 35441670 Free PMC article.
The added value of H2 antagonists in premedication regimens during paclitaxel treatment.
Cox JM, van Doorn L, Malmberg R, Oomen-de Hoop E, Bosch TM, van den Bemt PMLA, Boere IA, Jager A, Mathijssen RHJ, van Leeuwen RWF. Cox JM, et al. Among authors: van doorn l. Br J Cancer. 2021 May;124(10):1647-1652. doi: 10.1038/s41416-021-01313-0. Epub 2021 Mar 24. Br J Cancer. 2021. PMID: 33762718 Free PMC article. Clinical Trial.
Feasibility of therapeutic drug monitoring of sorafenib in patients with liver or thyroid cancer.
Guchelaar NAD, van Eerden RAG, Groenland SL, Doorn LV, Desar IME, Eskens FALM, Steeghs N, van Erp NP, Huitema ADR, Mathijssen RHJ, Koolen SLW; Dutch Pharmacology Oncology Group. Guchelaar NAD, et al. Among authors: doorn lv. Biomed Pharmacother. 2022 Sep;153:113393. doi: 10.1016/j.biopha.2022.113393. Epub 2022 Jul 11. Biomed Pharmacother. 2022. PMID: 35834987 Free article.
31 results